MedTrace Logo

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine

NCT02003313 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1260

Last updated 2015-09-22

No results posted yet for this study

Summary

The purpose of this double-blind study is to evaluate the safety, reactogenicity and immunogenicity of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine in 2 to 30 years-old Children and Adults. All subjects will receive 1 dose of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine.

Conditions

Interventions

BIOLOGICAL

Group T

0.5ml, Intramuscular

BIOLOGICAL

Group C

0.5ml, Intramuscular

Sponsors & Collaborators

  • Beijing Minhai Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • nianmin shi · Beijing chaoyang district center for disease control and prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-05-31
Completion
2015-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003313 on ClinicalTrials.gov